Literature DB >> 12547214

Increased duodenal DMT-1 expression and unchanged HFE mRNA levels in HFE-associated hereditary hemochromatosis and iron deficiency.

V Byrnes1, S Barrett, E Ryan, T Kelleher, C O'Keane, B Coughlan, J Crowe.   

Abstract

HFE-associated hereditary hemochromatosis is characterized by imbalances of iron homeostasis and alterations in intestinal iron absorption. The identification of the HFE gene and the apical iron transporter divalent metal transporter-1, DMT-1, provide a direct method to address the mechanisms of iron overload in this disease. The aim of this study was to evaluate the regulation of duodenal HFE and DMT-1 gene expression in HFE-associated hereditary hemochromatosis. Small bowel biopsies and serum iron indices were obtained from a total of 33 patients. The study population comprised 13 patients with hereditary hemochromatosis (C282Y homozygous), 10 patients with iron deficiency anemia, and 10 apparently healthy controls, all of whom were genotyped for the two common mutations in the HFE gene (C282Y and H63D). Total RNA was isolated from tissue and amplified via RT-PCR for HFE, DMT-1, and the internal control GAPDH. DMT-1 protein expression was additionally assessed by immunohistochemistry. Levels of HFE mRNA did not differ significantly between patient groups (P = 0.09), specifically between C282Y homozygotes and iron deficiency anemic patients, when compared to controls (P = 0.09, P = 0.9, respectively). In contrast, DMT-1 mRNA levels were at least twofold greater in patients with hereditary hemochromatosis and iron deficiency anemia when compared to controls (P = 0.02, P = 0.01, respectively). Heightened DMT-1 protein expression correlated with mRNA levels in all patients. Loss of HFE function in hereditary hemochromatosis is not derived from inhibition of its gene expression. DMT-1 expression in C282Y homozygote subjects is consistent with the hypothesis of a "paradoxical" duodenal iron deficiency in hereditary hemochromatosis. The observed twofold upregulation of the DMT-1 is consistent with the slow but steady increase in body iron stores observed in those presenting with clinical features of hereditary hemochromatosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12547214     DOI: 10.1006/bcmd.2002.0554

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  9 in total

1.  Haemochromatosis protein is expressed on the terminal web of enterocytes in proximal small intestine of the rat.

Authors:  A R West; C Thomas; J Sadlier; P S Oates
Journal:  Histochem Cell Biol       Date:  2005-10-06       Impact factor: 4.304

2.  Diagnosis and management of iron deficiency anemia in the 21st century.

Authors:  Terri D Johnson-Wimbley; David Y Graham
Journal:  Therap Adv Gastroenterol       Date:  2011-05       Impact factor: 4.409

3.  Increased DMT1 but not IREG1 or HFE mRNA following iron depletion therapy in hereditary haemochromatosis.

Authors:  T Kelleher; E Ryan; S Barrett; M Sweeney; V Byrnes; C O'Keane; J Crowe
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

4.  Relationship between gene expression of duodenal iron transporters and iron stores in hemochromatosis subjects.

Authors:  James E Nelson; Virginia R Mugford; Ellen Kilcourse; Richard S Wang; Kris V Kowdley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-11-05       Impact factor: 4.052

Review 5.  H(+)-coupled divalent metal-ion transporter-1: functional properties, physiological roles and therapeutics.

Authors:  Ali Shawki; Patrick B Knight; Bryan D Maliken; Eric J Niespodzany; Bryan Mackenzie
Journal:  Curr Top Membr       Date:  2012       Impact factor: 3.049

Review 6.  Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  Drug Des Devel Ther       Date:  2016-01-29       Impact factor: 4.162

Review 7.  The Combined Application of the Caco-2 Cell Bioassay Coupled with In Vivo (Gallus gallus) Feeding Trial Represents an Effective Approach to Predicting Fe Bioavailability in Humans.

Authors:  Elad Tako; Haim Bar; Raymond P Glahn
Journal:  Nutrients       Date:  2016-11-18       Impact factor: 5.717

8.  Mechanistic basis of the inhibition of SLC11/NRAMP-mediated metal ion transport by bis-isothiourea substituted compounds.

Authors:  Cristina Manatschal; Jonai Pujol-Giménez; Marion Poirier; Jean-Louis Reymond; Matthias A Hediger; Raimund Dutzler
Journal:  Elife       Date:  2019-12-05       Impact factor: 8.140

Review 9.  New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications.

Authors:  George J Kontoghiorghes; Annita Kolnagou; Theodora Demetriou; Marina Neocleous; Christina N Kontoghiorghe
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.